Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer

Carlos Robles, A. J. Furst, P. Sriratana, S. Lai, L. Chua, E. Donnelly, J. Solomon, M. Sundaram, Lynn G Feun, Niramol Savaraj

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A phase II trial of vinorelbine and low dose prednisone in hormone-refractory metastatic prostate cancer was conducted in order to investigate its safety, efficacy and impact on quality of life. Vinorelbine was administered at the dose of 25 mg/m2 i.v. weekly for 12 weeks and then biweekly, along with 10 mg of daily oral prednisone until time of progression. Fourteen patients, median age of 74 years, were treated. The treatment was generally well tolerated with leukopenia and anemia as the major side effects. One patient achieved partial remission and eleven remained with stable disease. One of the eleven patients with stable disease had a dramatic PSA response from 1000 to 236 ng/ml; seven of these progressed after week twelve when vinorelbine was given biweekly. PSA response occurred in 5 of 14 patients. The median time to progression was 28 weeks and the median survival was 17 months. Nine out of the 14 accrued patients were evaluable for quality of life assessment. Five of them improved, three remained unchanged and two had a slight worsening. Four patients had improvement in pain control and fatigue. Our preliminary data suggest that the combination of vinorelbine/prednisone has modest activity in metastatic prostate cancer with a very favorable toxicity profile and is very well tolerated in this group of elderly patients.

Original languageEnglish
Pages (from-to)885-889
Number of pages5
JournalOncology Reports
Volume10
Issue number4
StatePublished - Jul 1 2003

Fingerprint

Prednisone
Prostatic Neoplasms
Hormones
Therapeutics
Quality of Life
Leukopenia
vinorelbine
Fatigue
Anemia
Safety
Pain
Survival

Keywords

  • Prednisone
  • Prostate cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. / Robles, Carlos; Furst, A. J.; Sriratana, P.; Lai, S.; Chua, L.; Donnelly, E.; Solomon, J.; Sundaram, M.; Feun, Lynn G; Savaraj, Niramol.

In: Oncology Reports, Vol. 10, No. 4, 01.07.2003, p. 885-889.

Research output: Contribution to journalArticle

Robles, C, Furst, AJ, Sriratana, P, Lai, S, Chua, L, Donnelly, E, Solomon, J, Sundaram, M, Feun, LG & Savaraj, N 2003, 'Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer', Oncology Reports, vol. 10, no. 4, pp. 885-889.
Robles C, Furst AJ, Sriratana P, Lai S, Chua L, Donnelly E et al. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncology Reports. 2003 Jul 1;10(4):885-889.
Robles, Carlos ; Furst, A. J. ; Sriratana, P. ; Lai, S. ; Chua, L. ; Donnelly, E. ; Solomon, J. ; Sundaram, M. ; Feun, Lynn G ; Savaraj, Niramol. / Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. In: Oncology Reports. 2003 ; Vol. 10, No. 4. pp. 885-889.
@article{0e09d2a0de6c4770b898f90d30edf63b,
title = "Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer",
abstract = "A phase II trial of vinorelbine and low dose prednisone in hormone-refractory metastatic prostate cancer was conducted in order to investigate its safety, efficacy and impact on quality of life. Vinorelbine was administered at the dose of 25 mg/m2 i.v. weekly for 12 weeks and then biweekly, along with 10 mg of daily oral prednisone until time of progression. Fourteen patients, median age of 74 years, were treated. The treatment was generally well tolerated with leukopenia and anemia as the major side effects. One patient achieved partial remission and eleven remained with stable disease. One of the eleven patients with stable disease had a dramatic PSA response from 1000 to 236 ng/ml; seven of these progressed after week twelve when vinorelbine was given biweekly. PSA response occurred in 5 of 14 patients. The median time to progression was 28 weeks and the median survival was 17 months. Nine out of the 14 accrued patients were evaluable for quality of life assessment. Five of them improved, three remained unchanged and two had a slight worsening. Four patients had improvement in pain control and fatigue. Our preliminary data suggest that the combination of vinorelbine/prednisone has modest activity in metastatic prostate cancer with a very favorable toxicity profile and is very well tolerated in this group of elderly patients.",
keywords = "Prednisone, Prostate cancer, Vinorelbine",
author = "Carlos Robles and Furst, {A. J.} and P. Sriratana and S. Lai and L. Chua and E. Donnelly and J. Solomon and M. Sundaram and Feun, {Lynn G} and Niramol Savaraj",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "10",
pages = "885--889",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer

AU - Robles, Carlos

AU - Furst, A. J.

AU - Sriratana, P.

AU - Lai, S.

AU - Chua, L.

AU - Donnelly, E.

AU - Solomon, J.

AU - Sundaram, M.

AU - Feun, Lynn G

AU - Savaraj, Niramol

PY - 2003/7/1

Y1 - 2003/7/1

N2 - A phase II trial of vinorelbine and low dose prednisone in hormone-refractory metastatic prostate cancer was conducted in order to investigate its safety, efficacy and impact on quality of life. Vinorelbine was administered at the dose of 25 mg/m2 i.v. weekly for 12 weeks and then biweekly, along with 10 mg of daily oral prednisone until time of progression. Fourteen patients, median age of 74 years, were treated. The treatment was generally well tolerated with leukopenia and anemia as the major side effects. One patient achieved partial remission and eleven remained with stable disease. One of the eleven patients with stable disease had a dramatic PSA response from 1000 to 236 ng/ml; seven of these progressed after week twelve when vinorelbine was given biweekly. PSA response occurred in 5 of 14 patients. The median time to progression was 28 weeks and the median survival was 17 months. Nine out of the 14 accrued patients were evaluable for quality of life assessment. Five of them improved, three remained unchanged and two had a slight worsening. Four patients had improvement in pain control and fatigue. Our preliminary data suggest that the combination of vinorelbine/prednisone has modest activity in metastatic prostate cancer with a very favorable toxicity profile and is very well tolerated in this group of elderly patients.

AB - A phase II trial of vinorelbine and low dose prednisone in hormone-refractory metastatic prostate cancer was conducted in order to investigate its safety, efficacy and impact on quality of life. Vinorelbine was administered at the dose of 25 mg/m2 i.v. weekly for 12 weeks and then biweekly, along with 10 mg of daily oral prednisone until time of progression. Fourteen patients, median age of 74 years, were treated. The treatment was generally well tolerated with leukopenia and anemia as the major side effects. One patient achieved partial remission and eleven remained with stable disease. One of the eleven patients with stable disease had a dramatic PSA response from 1000 to 236 ng/ml; seven of these progressed after week twelve when vinorelbine was given biweekly. PSA response occurred in 5 of 14 patients. The median time to progression was 28 weeks and the median survival was 17 months. Nine out of the 14 accrued patients were evaluable for quality of life assessment. Five of them improved, three remained unchanged and two had a slight worsening. Four patients had improvement in pain control and fatigue. Our preliminary data suggest that the combination of vinorelbine/prednisone has modest activity in metastatic prostate cancer with a very favorable toxicity profile and is very well tolerated in this group of elderly patients.

KW - Prednisone

KW - Prostate cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=1542577585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542577585&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 885

EP - 889

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -